Credit Suisse’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-73,061
| Closed | -$353K | – | 4272 |
|
|
2020
Q1 | $353K | Sell |
73,061
-8,290
| -10% | -$53.7K | ﹤0.01% | 3313 |
|
|
2019
Q4 | $864K | Buy |
81,351
+49,403
| +155% | +$490K | ﹤0.01% | 3236 |
|
|
2019
Q3 | $333K | Buy |
31,948
+13,387
| +72% | +$175K | ﹤0.01% | 3648 |
|
|
2019
Q2 | $284K | Sell |
18,561
-2,019
| -10% | -$29.2K | ﹤0.01% | 3707 |
|
|
2019
Q1 | $266K | Buy |
20,580
+6,539
| +47% | +$73.9K | ﹤0.01% | 3653 |
|
|
2018
Q4 | $133K | Buy |
+14,041
| New | +$182K | ﹤0.01% | 3736 |
|
|
2018
Q3 | – | Sell |
-45,598
| Closed | -$732K | – | 4103 |
|
|
2018
Q2 | $732K | Buy |
+45,598
| New | +$814K | ﹤0.01% | 3230 |
|
|
2017
Q4 | – | Sell |
-16,756
| Closed | -$186K | – | 4302 |
|
|
2017
Q3 | $186K | Buy |
+16,756
| New | +$158K | ﹤0.01% | 3954 |
|
|
2017
Q1 | – | Sell |
-11,483
| Closed | -$123K | – | 4182 |
|
|
2016
Q4 | $123K | Buy |
+11,483
| New | +$139K | ﹤0.01% | 3914 |
|
|
2016
Q3 | – | Sell |
-10,567
| Closed | -$72K | – | 4331 |
|
|
2016
Q2 | $72K | Buy |
+10,567
| New | +$66.7K | ﹤0.01% | 4111 |
|
|
2015
Q3 | – | Sell |
-10,545
| Closed | -$124K | – | 4583 |
|
|
2015
Q2 | $124K | Buy |
+10,545
| New | +$146K | ﹤0.01% | 4350 |
|
|
2015
Q1 | – | Sell |
-23,809
| Closed | -$406K | – | 4673 |
|
|
2014
Q4 | $406K | Buy |
+23,809
| New | +$343K | ﹤0.01% | 3855 |
|
|
2014
Q3 | – | Sell |
-10,557
| Closed | -$155K | – | 4742 |
|
|
2014
Q2 | $155K | Sell |
10,557
-23,255
| -69% | -$357K | ﹤0.01% | 4446 |
|
|
2014
Q1 | $689K | Sell |
33,812
-9,660
| -22% | -$234K | ﹤0.01% | 3464 |
|
|
2013
Q4 | $852K | Buy |
+43,472
| New | +$1.16M | ﹤0.01% | 3400 |
|
Credit Suisse's STML Position: Q2 2020 in Review
Credit Suisse sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 73,061 shares — an estimated $353K sold.
Credit Suisse first reported a position in STML in Q4 2013 and held it in 15 quarters. The position peaked at $864K in Q4 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Credit Suisse reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Credit Suisse sold 73,061 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $353K.
- Credit Suisse first reported a position in Stemline Therapeutics, Inc. in Q4 2013 and held it in 15 quarters.
- Credit Suisse's Stemline Therapeutics, Inc. position peaked at $864K in Q4 2019.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Credit Suisse's 13F filing for Q2 2020, filed 12 Aug 2020.